Lung disorders such as asthma, acute respiratory distress syndrome (ARDS), chronic obstructive lung disease (COPD), and interstitial lung disease (ILD) show a few common threads of pathogenic mechanisms: inflammation, aberrant immune activity, infection, and fibrosis. Currently no modes of effective results are available for ILD or emphysema. Being anti-inflammatory, immunomodulatory, and regenerative in nature, the administration of mesenchymal stem cells (MSCs) has shown the capacity to control immune dysfunction and inflammation in the lung. The intravenous infusion of MSCs, the common mode of delivery, is followed by their entrapment in lung vasculature before MSCs reach to other organ systems thus indicating the feasible and promising approach of MSCs for lung diseases. In this review, we discuss the mechanistic basis for MSCs for asthma, ARDS, COPD, and ILD.
Exploring the Benefits of IV Therapy: What You Need to Know
As healthcare continues to evolve, IV therapy has emerged as a popular method of delivering essential nutrients directly into the